Simcere Pharmaceutical Group (HKSE:02096) Stock Based Compensation : HK$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Stock Based Compensation?

Simcere Pharmaceutical Group's Stock Based Compensation for the six months ended in Dec. 2023 was HK$0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0 Mil.

Simcere Pharmaceutical Group Stock Based Compensation Historical Data

The historical data trend for Simcere Pharmaceutical Group's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Stock Based Compensation Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

15.75

38.88

76.40

154.43

13.26

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Stock Based Compensation	Get a 7-Day Free Trial							-	-	-	-	-

Simcere Pharmaceutical Group Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

Simcere Pharmaceutical Group Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Stock Based Compensation

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines